Processing PDF: /home/ngobiro/projects/pngobiro.github.io/colleges/kmtc/diploma/Diploma in Kenya Registered Community Health Nursing/Year 1/Cardiovascular Nursing/03_Common_Cardiovascular_Disorders/02_Hypertension/pdfs/5. hypertension management_.pdf
Starting PDF processing...
PDF processing started. ID: 2025_06_28_ac6cd7de8d39a5495ea7g
Polling PDF status (ID: 2025_06_28_ac6cd7de8d39a5495ea7g)...
Attempt 1: Status = completed, Progress = 100.0%
PDF processing completed successfully.
Fetching MMD result (ID: 2025_06_28_ac6cd7de8d39a5495ea7g)...

--- Converted MMD Start ---
\section*{Drug Therapy of Hypertension}

EO

\section*{Classification of Hypertension}
\begin{tabular}{|c|c|c|}
\hline \begin{tabular}{c} 
BP \\
CLASSIFICATION
\end{tabular} & SBP & DBP \\
\hline Normal & $<120$ and & $<80$ \\
\hline Prehypertension & $120-139$ or & $80-89$ \\
\hline Stage 1 HTN & $140-159$ or & $90-99$ \\
\hline Stage 2 HTN & $\geq 160$ & $\geq 100$ \\
\hline
\end{tabular}

\section*{Classification Based On Office BP Measurement}
\begin{tabular}{|l|l|l|l|}
\hline Category & Systolic (mm Hg ) & & Diastolic (mm Hg ) \\
\hline Normal BP & <130 & and & <85 \\
\hline High-normal BP & 130-139 & and/or & 85-89 \\
\hline Grade 1 hypertension & 140-159 & and/or & 90-99 \\
\hline Grade 2 hypertension & $\geq 160$ & and/or & $\geq 100$ \\
\hline
\end{tabular}
\begin{tabular}{|l|l|l|}
\hline \multicolumn{3}{|l|}{Table 2. Changes in blood pressure classification} \\
\hline JNC 6 Category & & JNC 7 Category \\
\hline & SBP/DBP & \\
\hline Optimal & <120/80 & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-04.jpg?height=115\&width=271\&top_left_y=519\&top_left_x=1699) \\
\hline Normal Borderline & 120-129/80-84 130-139/85-89 & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-04.jpg?height=242\&width=299\&top_left_y=664\&top_left_x=1704) \\
\hline Hypertension & $\geq 140 / 90$ & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-04.jpg?height=101\&width=806\&top_left_y=905\&top_left_x=1697) \\
\hline Stage 1 Stage 2 Stage 3 & 140-159/90-99 160-179/100-109 $\geq 180 / 110$ & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-04.jpg?height=309\&width=635\&top_left_y=1019\&top_left_x=1697) \\
\hline
\end{tabular}
1) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
2) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-71.

\section*{Prevalence of Hypertension in the US}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-05.jpg?height=1482&width=2579&top_left_y=333&top_left_x=180)

\section*{Risk of Untreated Hypertension}
- Cerebrovascular Accidents
- Coronary events
- Heart failure
- Progression of renal disease
- Progression to severe hypertension
- All cause mortality

\section*{Secondary Hypertension}
- Renal parenchymal disease
- UA, spot urine protein/creatinine, serum creatinine, USG.
- Renovascular
- Captopril scan
- Coarctation
- Lower Extremity BP
- Primary aldosteronism
- Serum and urinary K
- Plasma renin and aldosterone ratio
- Pheochromocytoma
- Spot urine for metanephrine/creatinine

\section*{Basic and Optional Laboratory Tests for Primary Hypertension}
\begin{tabular}{|l|l|}
\hline \multirow[t]{8}{*}{Basic testing} & Fasting blood glucose* \\
\hline & Complete blood count \\
\hline & Lipid profile \\
\hline & Serum creatinine with eGFR* \\
\hline & Serum sodium, potassium, calcium* \\
\hline & Thyroid-stimulating hormone \\
\hline & Urinalysis \\
\hline & Electrocardiogram \\
\hline \multirow[t]{3}{*}{Optional testing} & Echocardiogram \\
\hline & Uric acid \\
\hline & Urinary albumin to creatinine ratio \\
\hline
\end{tabular}
*May be included in a comprehensive metabolic panel. eGFR indicates estimated glomerular filtration rate.

\section*{Investigations}
- ECG

CXR
- Urine analysis
- Blood glucose, hematocrit
- Basic metabolic panel uecs, Uric acid,
- Lipid profile after 9-12 hour fast
- Urine microalbumin

\section*{Risk Stratification}
- Hypertension
- Smoking
- Obesity (BMI $\geq 30 \mathrm{~kg} / \mathrm{m}^{2}$ )
- Dyslipidemia
- Diabetes
- Microalbuminuria or GFR $<60 \mathrm{ml} / \mathrm{min}$
- Age > 55 (men), 65 (women)
- Family history of CVD
(Men<55, Women <65)
-Metabolic Syndrome

\section*{Target Organ Damage}
- Heart Disease
- CAD (Angina, myocardial infarction, coronary revascularization
- Left Ventricular Hypertrophy
- Heart Failure
- Stroke/TIA
- Chronic kidney disease
- Peripheral arterial disease
- Retinopathy

\section*{Goals of Therapy}
-BP $<140 / 90 \mathrm{mmHg}$
-BP $<130 / 80 \mathrm{mmHg}$ in patients with diabetes or chronic kidney disease.
- Achieve SBP goal especially in persons $\geq 50$ years of age.

\section*{Cardiovascular Benefits of Treatment of Hypertension}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-13.jpg?height=1396&width=2433&top_left_y=339&top_left_x=268)

Hebert et al, Archives Int Med 1993

\section*{Risk Reduction (\%) for $\mathbf{1 0 ~ m m ~ H g}$ fall in SBP - 613,815 patients}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-14.jpg?height=1512&width=1884&top_left_y=430&top_left_x=289)

\section*{CVD Risk Factors Common in Patients With Hypertension}
\begin{tabular}{|l|l|}
\hline Modifiable Risk Factors* & Relatively Fixed Risk Factors $\boldsymbol{\dagger}$ \\
\hline \begin{tabular}{l}
- Current cigarette smoking, secondhand smoking \\
- Diabetes mellitus \\
- Dyslipidemia/hypercholesterolemia \\
- Overweight/obesity \\
- Physical inactivity/low fitness \\
- Unhealthy diet
\end{tabular} & \begin{tabular}{l}
- CKD \\
- Family history \\
- Increased age \\
- Low socioeconomic/educational status \\
- Male sex \\
- Obstructive sleep apnea \\
- Psychosocial stress
\end{tabular} \\
\hline
\end{tabular}

\footnotetext{
*Factors that can be changed and, if changed, may reduce CVD risk. $\dagger$ Factors that are difficult to change (CKD, low socioeconomic/educational status, obstructive sleep apnea, cannot be changed (family history, increased age, male sex), or, if changed through the use of current intervention techniques, may not reduce CVD risk (psychosocial stress). CKD indicates chronic kidney disease; and CVD, cardiovascular disease.
}

Initiation of BP Lowering Treatment
(Life style changes and medications) at different initial office BP levels
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-16.jpg?height=1460&width=2392&top_left_y=471&top_left_x=214)

HMOD - Hypertension
Mediated Organ Damage

\section*{Nonpharmacological Interventions}
\begin{tabular}{|l|l|l|}
\hline COR & LOE & Recommendations for Nonpharmacological Interventions \\
\hline I & A & Weight loss is recommended to reduce BP in adults with elevated BP or hypertension who are overweight or obese. \\
\hline I & A & A heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, that facilitates achieving a desirable weight is recommended for adults with elevated BP or hypertension. \\
\hline I & A & Sodium reduction is recommended for adults with elevated BP or hypertension. \\
\hline I & A & Potassium supplementation, preferably in dietary modification, is recommended for adults with elevated BP or hypertension, unless contraindicated by the presence of CKD or use of drugs that reduce potassium excretion. \\
\hline
\end{tabular}

\section*{Nonpharmacological Interventions (cont.)}
\begin{tabular}{|l|l|l|}
\hline COR & LOE & Recommendations for Nonpharmacological Interventions \\
\hline I & A & Increased physical activity with a structured exercise program is recommended for adults with elevated BP or hypertension. \\
\hline I & A & Adult men and women with elevated BP or hypertension who currently consume alcohol should be advised to drink no more than 2 and 1 standard drinks* per day, respectively. \\
\hline
\end{tabular}
*In the United States, 1 "standard" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about $5 \%$ alcohol), 5 oz of wine (usually about $12 \%$ alcohol), and 1.5 oz of distilled spirits (usually about $40 \%$ alcohol).

\section*{Drug Therapy}

In previous guidelines 5 major drug classes (ACEIs, ARBs, BBs, CCBs, Ds) were recommended based on
- Proven ability to reduce BP
- CV event reduction in placebo-controlled studies
- Broad equivalence in overall CV morbidity/mortality
- Conclusion that benefit predominantly derives from BP lowering

\section*{Approach of Antihypertensive treatment}
- Increasing dose of initial monotherapy.
- Monotherapy substitution.
- "Stepped - care" approach (monotherapy with subsequent addition of other drugs).
- Initial two drug combination treatment.
- Use of single pill combinations.

\section*{Monotherapy vs. Combination}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-21.jpg?height=1553&width=2381&top_left_y=365&top_left_x=309)

\section*{Rationale for initial two drug-combination therapy in most patients}
- Greater BP reduction even vs maximum dose monotherapy.
- Reduced heterogeneity of the BP response to initial therapy.
- Steeper dose-response relationship with treatment uptitration.
- No/small increase in risk of hypotensive episodes (even in grade I hypertension).
- More frequent BP control after 1 year
- Better adherence to treatment
- Reduced therapeutic inertia
- Reduce CV events (grade I hypertension, HOPE-3)

\section*{Guideline Basis for Compelling Indications for Individual Drug Classes}

High Risk Conditions
Recommended Drugs
With Compelling Indication
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline Heart fallure & & & & & & \\
\hline Post-myocardlal Infaretien & & & & & & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=83\&width=54\&top_left_y=965\&top_left_x=2354) \\
\hline & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=61\&width=65\&top_left_y=1141\&top_left_x=1035) & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=50\&width=49\&top_left_y=1145\&top_left_x=1306) & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=50\&width=49\&top_left_y=1145\&top_left_x=1603) & & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=50\&width=54\&top_left_y=1145\&top_left_x=1986) & \\
\hline High coronary disease rlsk & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=69\&width=65\&top_left_y=1265\&top_left_x=1035) & & & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=91\&width=58\&top_left_y=1243\&top_left_x=1839) & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=65\&width=49\&top_left_y=1269\&top_left_x=1994) & \\
\hline Dlabetes & & & & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=39\&width=73\&top_left_y=1449\&top_left_x=1824) & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=77\&width=54\&top_left_y=1389\&top_left_x=1986) & \\
\hline Chronic Kldney Disease & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=69\&width=61\&top_left_y=1521\&top_left_x=1035) & & ![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-23.jpg?height=65\&width=49\&top_left_y=1521\&top_left_x=1603) & & & \\
\hline
\end{tabular}

Recurrent stroke prevention

JNC - VII Report, JAMA, 2003;289:2560-2572

\section*{Core drug treatment strategy for uncomplicated hypertension}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-24.jpg?height=1220&width=2381&top_left_y=524&top_left_x=223)

The core algorithm is also appropriate for most patients with HMOD, CVA, DM, or PAD

\section*{Drug treatment strategy for hypertension + DM}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-25.jpg?height=1329&width=2601&top_left_y=514&top_left_x=124)

\section*{Drug treatment strategy for hypertension CAD}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-26.jpg?height=1280&width=2649&top_left_y=434&top_left_x=111)

\section*{Pathophysiology of heart failure}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-27.jpg?height=1337&width=1933&top_left_y=372&top_left_x=678)

FIGURE 13-2 Some compensatory responses that occur during congestive heart failure. In addition to the effects shown, sympathetic discharge facilitates renin release, and angiotensin II increases norepinephrine release by sympathetic nerve endings (dashed arrows).

\section*{Hypertension and Heart Failure With Reduced EF}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-28.jpg?height=699&width=2239&top_left_y=471&top_left_x=350)

\section*{Drug treatment strategy for hypertension and CKD}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-29.jpg?height=1247&width=2541&top_left_y=462&top_left_x=165)

\section*{Drug treatment strategy for hypertension and AF}
![](https://cdn.mathpix.com/cropped/2025_06_28_ac6cd7de8d39a5495ea7g-30.jpg?height=956&width=2442&top_left_y=678&top_left_x=230)
--- Converted MMD End ---
